Every 10-Q that Teva Pharmaceutical Industries Limited (TEVA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TEVA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TEVA filings page.
Teva Pharmaceutical Industries Limited reported Q2 2026 net revenues of $4,142 million, roughly flat versus $4,176 million a year earlier, but recorded a net loss attributable to Teva of $576 million, compared with net income of $282 million. The loss reflects sharply higher R&D expense of $970 million, including a $724 million in‑process R&D charge from the Emalex Biosciences acquisition, and $230 million of legal settlements and loss contingencies.
For the first six months of 2026, net revenues were $8,124 million and net loss attributable to Teva was $207 million. Operating cash flow was $371 million, while investing activities used $263 million, largely driven by Emalex. At June 30 2026, cash and cash equivalents were $3,655 million, total assets $39,857 million, total equity $7,757 million, short‑term debt $4,500 million and long‑term senior notes and loans $12,092 million. Teva continues to classify its API business as held for sale, with $1,794 million of related assets and $313 million of liabilities, and maintains a $4,854 million provision for legal settlements and loss contingencies related to ongoing matters.
Teva Pharmaceutical Industries Limited reported another profitable quarter with net revenues of $3,982 million for the three months ended March 31, 2026, up slightly from $3,891 million a year earlier, as stronger gross profit more than offset higher selling and marketing costs.
Net income attributable to Teva rose to $369 million from $214 million, and diluted earnings per share increased to $0.31 from $0.18. Operating income improved to $652 million, helped by much lower intangible asset impairments compared with the prior year.
Cash and cash equivalents increased to $3,741 million while net cash used in operating activities was $40 million, influenced by a $617 million net use of cash in working capital. Total assets were $40,040 million and total equity rose to $8,232 million.
Teva continued to adjust its portfolio and capital structure. Senior notes and loans decreased to $14,015 million, and assets held for sale of $1,794 million mainly related to the API business remain classified for divestiture. Legal provisions for settlements and loss contingencies totaled $4,680 million, with $72 million of related expenses recorded this quarter.
Strategic R&D and funding transactions advanced the pipeline. Teva agreed to acquire Emalex Biosciences for $700 million plus up to $200 million in milestones, and entered funding agreements with Blackstone Life Sciences and Royalty Pharma that could provide up to $900 million across key late-stage programs. Several collaboration partners, including Sanofi, Alvotech, MedinCell and others, progressed Phase 3 or registration-stage assets, supporting Teva’s Pivot to Growth strategy.
Teva Pharmaceutical Industries reported Q3 2025 results showing higher profitability. Net revenues were $4,480 million, up from $4,332 million a year ago. Operating income reached $882 million versus a loss last year, and net income attributable to Teva was $433 million (basic EPS $0.38; diluted $0.37). For the first nine months, net revenues were $12,547 million with net income of $930 million.
The balance sheet reflects $2,203 million in cash and cash equivalents, total assets of $39,856 million, and Teva shareholders’ equity of $7,250 million. Senior notes and loans were $16,766 million. Teva executed several 2025 note repayments and, in May 2025, issued new senior notes of $700 million (5.75% due 2030), €1,000 million (4.125% due 2031) and $500 million (6.00% due 2032). A June 2025 tender extinguished multiple tranches, resulting in a $10 million loss recorded in financial expenses. Shares outstanding were 1,147,282,512 as of September 30, 2025.